DexCom (DXCM)
(Delayed Data from NSDQ)
$115.79 USD
+0.49 (0.42%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $115.77 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$115.79 USD
+0.49 (0.42%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $115.77 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Zacks News
DexCom's (DXCM) G7 CGM System Now Connects to Apple Watch
by Zacks Equity Research
DexCom (DXCM) announces the direct connectivity of its G7 CGM system to Apple Watch for users in the United States, the UK, and Ireland.
DexCom (DXCM) Declines on Potential Competition for Stelo (revised)
by Zacks Equity Research
DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.
DexCom (DXCM) Declines on Potential Competition for Stelo
by Zacks Equity Research
DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor
by Zacks Equity Research
Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM.
Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
Haemonetics (HAE) Banks on Plasma Arm Growth Amid Rising Costs
by Zacks Equity Research
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Here is Why Growth Investors Should Buy DexCom (DXCM) Now
by Zacks Equity Research
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Ecolab (ECL) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its first-quarter sales despite business challenges.
QIAGEN (QGEN) Q1 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
QIAGEN (QGEN) Q1 results are driven by solid growth in consumables and ongoing higher instruments placements.
DexCom, Inc. (DXCM) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's Why You Should Buy Bruker (BRKR) Stock Right Now
by Zacks Equity Research
Bruker's (BRKR) strong potential across the NANO and BioSpin segments bodes well for investors.
Here's Why DexCom (DXCM) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues
by Zacks Equity Research
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
DexCom (DXCM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Wall Street Bulls Look Optimistic About DexCom (DXCM): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), DexCom (DXCM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter 2024 results are likely to reflect rising volumes across all channels.
Ahead of DexCom (DXCM) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Zacks Investment Ideas feature highlights: Vertiv, Align Technology and DexCom
by Zacks Equity Research
Vertiv, Align Technology and DexCom are part of the Zacks Investment Ideas article.
3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback
by Benjamin Rains
Long-term investors are often well-served to buy stocks amid bouts of weakness.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS
by Zacks Equity Research
Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.